Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Radiation after thyroid surgery may keep cancer at bay

NCT ID NCT06524167

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving radiation therapy within 6 weeks after surgery can help prevent thyroid cancer from coming back in people at high risk. It includes 80 patients with various types of thyroid cancer (except undifferentiated). The main goal is to see how long they stay free of local or regional recurrence. Researchers will also track overall survival, side effects, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy (external beam radiotherapy using IMRT or VMAT)
What this could lead to
If successful, this could show that adding radiotherapy after surgery improves local control and reduces recurrence in high-risk thyroid cancer patients.
What could go wrong
This is a small, real-world study (80 people) without a comparison group, so results may not be definitive. Radiotherapy can cause side effects like fatigue or skin irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with high recurrence risk locally advanced thyroid cancer

Ages

14 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients voluntarily join this study and sign an informed consent form; * Age: ≥ 14 years old,\<80 years old, male or female not limited; * Thyroid cancer diagnosed by histopathology, including differentiated thyroid cancer, medullary carcinoma, poorly differentiated carcinoma, etc; * High risk of local late recurrence, meeting any of the following criteria: 1. The surgery did not achieve R0 resection; 2. After neoadjuvant therapy; 3. Pathological types with poor prognosis, such as poorly differentiated cancer, CASTLE, etc; 4. Thyroid cancer with obvious extracapsular invasion, invading important structures such as the esophagus, trachea, and recurrent laryngeal nerve, requiring adjuvant radiotherapy; 5. For patients with distant metastasis, researchers need to determine the value of local treatment; * The main organ functions are normal; * Good compliance and cooperation with follow-up. Exclusion Criteria: * Untreated thyroid cancer or thyroid cancer that has only undergone surgical biopsy; * Within 5 years or simultaneously suffering from other active malignant tumors. Cured local tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, can be included in the group; * Previously received radiation therapy for the head and neck area; * Pregnant or lactating women; * There are other physical illnesses that affect patients' ability to receive standard treatment; * According to the researcher's judgment, there may be other factors that could force the subject to terminate the study midway, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the subject's safety or the collection of trial data; * Individuals with claustrophobia who are unable to undergo radiation therapy; * Other patients deemed unsuitable for inclusion by the treating physician.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thyroid cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.